Biocodex Inks Distribution Pact with Dr. Reddy’s to Market Its Flagship Products in Romania

HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories (NYSE: RDY) has entered into a strategic
alliance with Biocodex to market and distribute Biocodex products in the
Romanian market.

Biocodex has announced the change in partnership and effective October
1, 2015, Dr. Reddy’s has been given the complete rights for promotion
and distribution of the Biocodex products across Romania. Earlier,
AKACIA was in partnership with Biocodex for similar distribution pact.

With this new collaboration coming into existence, Dr. Reddy’s will aim
to develop the access of the Romanian patients to the Rx portfolio
including Biocodex’s well-known OTC products ENTEROL and OTIPAX.

ENTEROL: The ethical pharmaceutical specialty composed of lyophilised
Saccharomyces boulardii living cells in a concentration of 250 mg per
capsule, or per sachet registered in Romania in packs of 10 capsules and
sachets under the trademark ENTEROL.

OTIPAX: The ethical pharmaceutical specialty presented as an ear drop
solution containing phenazone and lidocaine hydrochloride, presented in
bottles of 15 ml registered in Romania under the trademark OTIPAX.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is
an integrated pharmaceutical company, committed to providing affordable
and innovative medicines for healthier lives. Through its three
businesses – Pharmaceutical Services & Active Ingredients, Global
Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of
products and services including APIs, custom pharmaceutical services,
generics, biosimilars and differentiated formulations. Our major
therapeutic areas of focus are gastro-intestinal, cardiovascular,
diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s
operates in markets across the globe. Our major markets include – USA,
Russia & CIS, Venezuela and India. For more information, log on to:

About Biocodex : Biocodex is an independent multinational
pharmaceutical company, founded in France in 1953. The company’s initial
focus was gastroenterology and specifically a unique probiotic
discovery, Saccharomyces boulardii, the first probiotic drug of its kind
that has a positive effect on the gut’s microflora. Today, Biocodex has
transformed itself beyond its probiotic drug roots, expanding its
portfolio into a multitude of therapeutic areas, such as:
gastroenterology, pediatric, pain management, neurology /psychiatry,
otolaryngology and rheumatology. Biocodex operates its own research and
development center, housing a diverse team of scientific researchers
with a vast array of experience. Biocodex’ scientific teams frequently
partner with major universities and research organizations worldwide and
are continually involved with some of the most provocative research in
medicine today. Biocodex has partnered with healthcare professionals for
60 years with the mission of developing meaningful solutions to today’s
challenging healthcare problems. Biocodex has grown into a multinational
research and development, manufacturing and commercial enterprise
operating in over 110 countries, via a network of 9 subsidiaries,
licenses, distributors and licensed retailers. 2014 Biocodex’
consolidated revenue was 235 million euros. The company employs more
than 1,000 persons worldwide.

Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the
management’s current views and assumptions and involve known or unknown
risks and uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in such
statements. In addition to statements which are forward-looking by
reason of context, the words “may,” “will,” “should,” “expects,”
“plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue” and similar expressions identify
forward-looking statements. Actual results, performance or events may
differ materially from those in such statements due to without
limitation, (i) general economic conditions such as performance of
financial markets, credit defaults, currency exchange rates, interest
rates, persistency levels and frequency / severity of insured loss
events, (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in
laws and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganisation, including
related integration issues.

The company assumes no obligation to update any information contained


Caroline Pardon, +33 1 41 24 49 39
Reddy’s Laboratories Ltd.

Calvin Printer, +91.40.4900 2121